Replies to post #108222 on Biotech Values

[BTH]

yes i know, the P3 JAK is in myelofibrosis, etc., but it still leaves no room for error with a market cap of $2 billion. Just my opinion.

[mcbio]

Re: INCY/JAK inhibitor

the phase 3 isn't in RA.

INCY is developing a JAK2 inhibitor for RA though, aren't they? I thought it was at least in Phase 2.